These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 24188686

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.
    Kim JY, Kim YJ, Lee KW, Lee JS, Kim DW, Kang SB, Lee HS, Jang NY, Kim JS, Kim JH.
    Jpn J Clin Oncol; 2013 Feb; 43(2):132-8. PubMed ID: 23204187
    [Abstract] [Full Text] [Related]

  • 3. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
    Lou YT, Chen CW, Fan YC, Chang WC, Lu CY, Wu IC, Hsu WH, Huang CW, Wang JY.
    PLoS One; 2014 Feb; 10(4):e0123973. PubMed ID: 25919688
    [Abstract] [Full Text] [Related]

  • 4. Effect of delay in adjuvant oxaliplatin-based chemotherapy for stage III colon cancer.
    Peixoto RD, Kumar A, Speers C, Renouf D, Kennecke HF, Lim HJ, Cheung WY, Melosky B, Gill S.
    Clin Colorectal Cancer; 2015 Mar; 14(1):25-30. PubMed ID: 25465343
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of single agent or combination adjuvant chemotherapy in elderly patients with colon cancer: a Canadian cancer institute experience.
    Kim CA, Spratlin JL, Armstrong DE, Ghosh S, Mulder KE.
    Clin Colorectal Cancer; 2014 Sep; 13(3):199-206. PubMed ID: 25088184
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.
    Kim SH, Shin SJ, Lee KY, Kim H, Kim TI, Kang DR, Hur H, Min BS, Kim NK, Chung HC, Roh JK, Ahn JB.
    Ann Surg Oncol; 2013 Oct; 20(11):3407-13. PubMed ID: 23943026
    [Abstract] [Full Text] [Related]

  • 8. Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer.
    Panchal JM, Lairson DR, Chan W, Du XL.
    Clin Colorectal Cancer; 2013 Jun; 12(2):113-21. PubMed ID: 23137529
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colon Cancer 2 study.
    Köhne CH, Bedenne L, Carrato A, Bouché O, Popov I, Gaspà L, Valladares M, Rougier P, Gog C, Reichardt P, Wils J, Pignatti F, Biertz F.
    Eur J Cancer; 2013 May; 49(8):1868-75. PubMed ID: 23571150
    [Abstract] [Full Text] [Related]

  • 12. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
    Chang MH, Lee IK, Si Y, Lee KS, Woo IS, Byun JH.
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872
    [Abstract] [Full Text] [Related]

  • 13. The efficacy of oral tegafur-uracil as maintenance therapy following intravenous 5-fluorouracil chemotherapy in stage III colon cancer.
    Hong KD, Lee SI, Moon HY.
    Hepatogastroenterology; 2012 Aug; 59(113):104-7. PubMed ID: 22251527
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.
    Schippinger W, Samonigg H, Schaberl-Moser R, Greil R, Thödtmann R, Tschmelitsch J, Jagoditsch M, Steger GG, Jakesz R, Herbst F, Hofbauer F, Rabl H, Wohlmuth P, Gnant M, Thaler J, Austrian Breast and Colorectal Cancer Study Group.
    Br J Cancer; 2007 Oct 22; 97(8):1021-7. PubMed ID: 17895886
    [Abstract] [Full Text] [Related]

  • 16. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim JY, Kim YH, Chang DK, Rhee PL, Kim DS, Yun H, Cho YB, Kim HC, Yun SH, Lee WY, Chun HK, Park YS.
    Cancer Chemother Pharmacol; 2010 Sep 22; 66(4):659-67. PubMed ID: 20033812
    [Abstract] [Full Text] [Related]

  • 17. Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial--the PRODIGE 22--ECKINOXE trial.
    Karoui M, Rullier A, Luciani A, Bonnetain F, Auriault ML, Sarran A, Monges G, Trillaud H, Le Malicot K, Leroy K, Sobhani I, Bardier A, Moreau M, Brindel I, Seitz JF, Taieb J.
    BMC Cancer; 2015 Jul 10; 15():511. PubMed ID: 26156156
    [Abstract] [Full Text] [Related]

  • 18. Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial.
    Taieb J, Puig PL, Bedenne L.
    Expert Rev Anticancer Ther; 2008 Feb 10; 8(2):183-9. PubMed ID: 18279058
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients.
    Chen D, Wen X, Song YS, Rhee YY, Lee TH, Cho NY, Han SW, Kim TY, Kang GH.
    Clin Epigenetics; 2016 Feb 10; 8():36. PubMed ID: 27051466
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.